{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:46:10Z","timestamp":1787161570607,"version":"build-2736575974"},"reference-count":70,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R01DA057264"],"award-info":[{"award-number":["1R01DA057264"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Med Care Res Rev"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Provision of medications for opioid use disorder (MOUD) programs in carceral settings is critical to reducing overdose during the high-risk period following release from incarceration. Efforts to expand carceral MOUD programs have increased in recent years. We conducted a narrative review to synthesize evidence on the implementation of MOUD in U.S. carceral facilities. We analyzed 36 studies from 2019 to 2023 using the Exploration, Preparation, Implementation, Sustainment framework. Findings highlight that MOUD in carceral settings requires significant resources, infrastructure, and staffing. MOUD diversion is a common concern, with program responses varying widely. Stigma against MOUD remains a challenge, particularly when treating pregnant people with OUD. Effective coordination between carceral and community stakeholders is critical for MOUD implementation and continuity of treatment postrelease. COVID-19 spurred innovation, increasing telehealth in carceral MOUD programs. Future research should explore MOUD program transition from early adoption to wide-scale implementation, considering external factors, sustainability, and evolving policies.<\/jats:p>","DOI":"10.1177\/10775587251345018","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:03:26Z","timestamp":1750917806000},"page":"439-453","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Implementation of Jail and Prison-Based Medication Treatment for Opioid Use Disorder Programs: A Narrative Synthesis"],"prefix":"10.1177","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-6943","authenticated-orcid":false,"given":"Cosima","family":"Lenz","sequence":"first","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Song","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alene","family":"Kennedy Hendricks","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Kramer","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sufrin","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"},{"name":"The Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fingerhood","sequence":"additional","affiliation":[{"name":"The Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Aarons G. A. Hurlburt M. Horwitz S. M. (2011). Advancing a conceptual model of evidence-based practice implementation in public service sectors. Administration and Policy in Mental Health 38(1) 4\u201323. https:\/\/doi.org\/10.1007\/s10488-010-0327-7","DOI":"10.1007\/s10488-010-0327-7"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Bandara S. Kennedy-Hendricks A. Merritt S. Barry C. L. Saloner B. (2021). Methadone and buprenorphine treatment in United States jails and prisons: Lessons from early adopters. Addiction 116(12) 3473\u20133481. https:\/\/doi.org\/10.1111\/add.15565","DOI":"10.1111\/add.15565"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Barnes C. A. Ponce A. N. Loewy R. (2021). Recommendations to Improve Medication-Assisted Treatment Implementation in Correctional Health. Psychiatric Services 72(2) 233\u2013234. https:\/\/doi.org\/10.1176\/appi.ps.202000527","DOI":"10.1176\/appi.ps.202000527"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Binswanger I. A. Blatchford P. J. Mueller S. R. Stern M. F. (2013). Mortality after prison release: Opioid overdose and other causes of death risk factors and time trends from 1999 to 2009. Annals of Internal Medicine 159(9) 592\u2013600. https:\/\/doi.org\/10.7326\/0003-4819-159-9-201311050-00005","DOI":"10.7326\/0003-4819-159-9-201311050-00005"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Binswanger I. A. Stern M. F. Deyo R. A. Heagerty P. J. Cheadle A. Elmore J. G. Koepsell T. D. (2007). Release from prison\u2014A high risk of death for former inmates. The New England Journal of Medicine 356(2) 157\u2013165. https:\/\/doi.org\/10.1056\/NEJMsa064115","DOI":"10.1056\/NEJMsa064115"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Blue T. R. Fletcher J. B. Monico L. B. Gordon M. S. Schwartz R. P. Mitchell S. G. (2023). Jail and treatment staff attitudes regarding MOUDs before and after an implementation intervention. Journal of Offender Rehabilitation 62(7) 411\u2013426. https:\/\/doi.org\/10.1080\/10509674.2023.2246446","DOI":"10.1080\/10509674.2023.2246446"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Booty M. D. Harp K. Batty E. Knudsen H. K. Staton M. Oser C. B. (2023). Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians. Journal of Substance Use and Addiction Treatment 149 209051. https:\/\/doi.org\/10.1016\/j.josat.2023.209051","DOI":"10.1016\/j.josat.2023.209051"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Brinkley-Rubinstein L. Peterson M. Clarke J. Macmadu A. Truong A. Pognon K. Parker M. Marshall B. D. L. Green T. Martin R. Stein L. Rich J. D. (2019). The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug and Alcohol Dependence 205 107514. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.06.016","DOI":"10.1016\/j.drugalcdep.2019.06.016"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Cates L. Brown A. R. (2023). Medications for opioid use disorder during incarceration and post-release outcomes. Health & Justice 11(1) 4. https:\/\/doi.org\/10.1186\/s40352-023-00209-w","DOI":"10.1186\/s40352-023-00209-w"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Cheng A. Badolato R. Segoshi A. McDonald R. Malone M. Vasudevan K. Badiei B. Sugarman A. Macdonald R. Mangat J. Giftos J. Lee J. D. Tofighi B. (2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study. Addiction Science & Clinical Practice 17(1) 4. https:\/\/doi.org\/10.1186\/s13722-022-00288-4","DOI":"10.1186\/s13722-022-00288-4"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Clark K. J. Vechinski J. Molfenter T. Taxman F. S. (2023). Cascade of care in the legal system: Best practices and goals for agencies providing care to patients concurrently navigating substance use disorders and criminal legal involvement. Journal of Drug Issues 55(1) 64\u201388. https:\/\/doi.org\/10.1177\/00220426231196304","DOI":"10.1177\/00220426231196304"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Donelan C. J. Hayes E. Potee R. A. Schwartz L. Evans E. A. (2021). COVID-19 and treating incarcerated populations for opioid use disorder. Journal of Substance Abuse Treatment 124 108216. https:\/\/doi.org\/10.1016\/j.jsat.2020.108216","DOI":"10.1016\/j.jsat.2020.108216"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Duncan A. Sanders N. Schiff M. Winkelman T. N. A. (2021). Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. Journal of Substance Abuse Treatment 121 108161. https:\/\/doi.org\/10.1016\/j.jsat.2020.108161","DOI":"10.1016\/j.jsat.2020.108161"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Evans E. A. Pivovarova E. Stopka T. J. Santelices C. Ferguson W. J. Friedmann P. D. (2022). Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. Journal of Substance Abuse Treatment 138 108746. https:\/\/doi.org\/10.1016\/j.jsat.2022.108746","DOI":"10.1016\/j.jsat.2022.108746"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Evans E. A. Wilson D. Friedmann P. D. (2022). Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence 231 109254. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109254","DOI":"10.1016\/j.drugalcdep.2021.109254"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Ferguson W. J. Johnston J. Clarke J. G. Koutoujian P. J. Maurer K. Gallagher C. White J. Nickl D. Taxman F. S. (2019). Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails. Health & Justice 7(1) 19. https:\/\/doi.org\/10.1186\/s40352-019-0100-2","DOI":"10.1186\/s40352-019-0100-2"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Flanagan Balawajder E. Ducharme L. Taylor B. G. Lamuda P. A. Kolak M. Friedmann P. D. Pollack H. A. Schneider J. A. (2024). Factors associated with the availability of medications for opioid use disorder in US jails. JAMA Network Open 7(9) e2434704. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.34704","DOI":"10.1001\/jamanetworkopen.2024.34704"},{"key":"e_1_3_2_19_1","unstructured":"Funk A. Ishee J. Paluzzi M. (2024 February 29). SAMHSA final rule codifies opioid treatment program telehealth and take-home medication flexibilities. Insights & Resources. Goodwin. https:\/\/www.goodwinlaw.com\/en\/insights\/publications\/2024\/02\/alerts-otherindustries-hltc-samhsa-final-rule-codifies-opioid-treatment"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Grella C. E. Ostile E. Scott C. K. Dennis M. Carnavale J. (2020). A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. The International Journal on Drug Policy 81 102768. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102768","DOI":"10.1016\/j.drugpo.2020.102768"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Grella C. E. Scott C. K. Dennis M. L. LaVallee R. A. (2023). Access to services for pregnant people with opioid use disorder in jails in the United States. Journal of Correctional Health Care: The Official Journal of the National Commission on Correctional Health Care 29(4) 299\u2013307. https:\/\/doi.org\/10.1089\/jchc.22.03.0023","DOI":"10.1089\/jchc.22.03.0023"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Hanna J. Kubiak S. Pasman E. Gaba A. Andre M. Smelson D. Pinals D. A. (2020). Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: Application of the consolidated framework for implementation research in a cross-system initiative. Journal of Substance Abuse Treatment 108 104\u2013114. https:\/\/doi.org\/10.1016\/j.jsat.2019.06.012","DOI":"10.1016\/j.jsat.2019.06.012"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Harrington C. Bailey A. Delorme E. Hano S. Evans E. A. (2023). \u201cAnd then COVID hits\u201d: A qualitative study of how jails adapted services to treat opioid use disorder during COVID-19. Substance Use & Misuse 58(2) 266\u2013274. https:\/\/doi.org\/10.1080\/10826084.2022.2155480","DOI":"10.1080\/10826084.2022.2155480"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Hartung D. M. McCracken C. M. Nguyen T. Kempany K. Waddell E. N. (2023). Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data. Journal of Substance Use and Addiction Treatment 147 208971. https:\/\/doi.org\/10.1016\/j.josat.2023.208971","DOI":"10.1016\/j.josat.2023.208971"},{"key":"e_1_3_2_25_1","unstructured":"Health Management Associates. (2023). Maryland learning collaborative to support opioid use disorder examinations and treatment act and Medication Assisted Treatment (MAT) implementation for justice-involved populations. https:\/\/gocpp.maryland.gov\/wp-content\/uploads\/Maryland-Learning-Collaborative-20230925-1.pdf"},{"key":"e_1_3_2_26_1","unstructured":"Hinton E. Pillai A. Published A. D. (2024 August 19). Section 1115 Waiver watch: Medicaid pre-release services for people who are incarcerated. KFF. https:\/\/www.kff.org\/medicaid\/issue-brief\/section-1115-waiver-watch-medicaid-pre-release-services-for-people-who-are-incarcerated\/"},{"key":"e_1_3_2_27_1","unstructured":"Homans M. Allen D. M. (2023). A review of Medication Assisted Treatment (MAT) in United States jails and prisons. https:\/\/cchcs.ca.gov\/wp-content\/uploads\/sites\/60\/MAT-in-United-States-Jails-and-Prisons-Final.pdf"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Kang A. Bailey A. Napoleon S. Martin R. (2023). Contextualizing medications for opioid use disorder and peer support service provision in the probation system with implementation science. Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-3607705\/v1","DOI":"10.21203\/rs.3.rs-3607705\/v1"},{"key":"e_1_3_2_29_1","unstructured":"Kang-Brown J. Zhang J. (2024). People in jail and prison in 2024. https:\/\/vera-institute.files.svdcdn.com\/production\/downloads\/publications\/People-in-Jail-and-Prison-in-2024-Full-Reportpdf.pdf"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Kaplowitz E. Truong A. Q. Berk J. Martin R. A. Clarke J. G. Wieck M. Rich J. Brinkley-Rubinstein L. (2022). Treatment preference for opioid use disorder among people who are incarcerated. Journal of Substance Abuse Treatment 137 108690. https:\/\/doi.org\/10.1016\/j.jsat.2021.108690","DOI":"10.1016\/j.jsat.2021.108690"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Kaplowitz E. Truong A. Q. Macmadu A. Berk J. Martin H. Burke C. Rich J. D. Brinkley-Rubinstein L. (2023). Anticipated barriers to sustained engagement in treatment with medications for opioid use disorder after release from incarceration. Journal of Addiction Medicine 17(1) 54\u201359. https:\/\/doi.org\/10.1097\/ADM.0000000000001029","DOI":"10.1097\/ADM.0000000000001029"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Kawasaki S. Hwang G. Buckner K. Francis E. Huffnagle S. Kraschnewski J. Vulgamore P. Lucas A. Barbour J. Crawford M. Thomas L. Fuller M. Meyers J. Swartzentruber G. Levine R. (2022). Collaborative health systems ECHO: The use of a tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in Pennsylvania. Substance Abuse 43(1) 892\u2013900. https:\/\/doi.org\/10.1080\/08897077.2021.2007519","DOI":"10.1080\/08897077.2021.2007519"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"King Z. Kramer C. Latkin C. Sufrin C. (2021). Access to treatment for pregnant incarcerated people with opioid use disorder: Perspectives from community opioid treatment providers. Journal of Substance Abuse Treatment 126 108338. https:\/\/doi.org\/10.1016\/j.jsat.2021.108338","DOI":"10.1016\/j.jsat.2021.108338"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Klemperer E. M. Wreschnig L. Crocker A. King-Mohr J. Ramniceanu A. Brooklyn J. R. Peck K. R. Rawson R. A. Evans E. A. (2023). The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement postrelease continuation of care and overdose. Journal of Substance Use and Addiction Treatment 152 209103. https:\/\/doi.org\/10.1016\/j.josat.2023.209103","DOI":"10.1016\/j.josat.2023.209103"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Krawczyk N. Bandara S. Merritt S. Shah H. Duncan A. McEntee B. Schiff M. Ahmad N. J. Whaley S. Latimore A. Saloner B. (2022). Jail-based treatment for opioid use disorder in the era of bail reform: A qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. Addiction Science & Clinical Practice 17(1) 30. https:\/\/doi.org\/10.1186\/s13722-022-00313-6","DOI":"10.1186\/s13722-022-00313-6"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Lam J. A. Lee H. I. S. Truong A. Q. Macmadu A. Clarke J. G. Rich J. Brockmann B. (2019). Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting. Journal of Substance Abuse Treatment 104 28\u201333. https:\/\/doi.org\/10.1016\/j.jsat.2019.06.001","DOI":"10.1016\/j.jsat.2019.06.001"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Ludwig A. Monico L. B. Blue T. Gordon M. S. Schwartz R. P. Mitchell S. G. (2022). Development and use of a checklist for the implementation of medication for opioid use disorder in jails. Implementation Research and Practice 3 26334895221101214. https:\/\/doi.org\/10.1177\/26334895221101214","DOI":"10.1177\/26334895221101214"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"MacArthur G. J. Minozzi S. Martin N. Vickerman P. Deren S. Bruneau J. Degenhardt L. Hickman M. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ 345 Article e5945. https:\/\/doi.org\/10.1136\/bmj.e5945","DOI":"10.1136\/bmj.e5945"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Macmadu A. Goedel W. C. Adams J. W. Brinkley-Rubinstein L. Green T. C. Clarke J. G. Martin R. A. Rich J. D. Marshall B. D. L. (2020). Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails. Drug and Alcohol Dependence 208 107858. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107858","DOI":"10.1016\/j.drugalcdep.2020.107858"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Martin M. Phillips M. A. Saxon M. Love K. Cessna L. Woodard D. L. Page M. Curry K. Paone A. Pennington-Stallcup B. Riley W. (2021). Recovery support specialists inside the jail: A program description of treatment engagement for opioid use disorder. International Journal of Prisoner Health 17(4) 497\u2013508. https:\/\/doi.org\/10.1108\/IJPH-12-2020-0102","DOI":"10.1108\/IJPH-12-2020-0102"},{"key":"e_1_3_2_41_1","unstructured":"Maruschak L. M. Minton T. D. Zeng Z. (2023). Opioid use disorder screening and treatment in local jails 2019. Bureau of Justice Statistics. https:\/\/bjs.ojp.gov\/library\/publications\/opioid-use-disorder-screening-and-treatment-local-jails-2019"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Matsumoto A. Santelices C. Evans E. A. Pivovarova E. Stopka T. J. Ferguson W. J. Friedmann P. D. (2022). Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. The International Journal on Drug Policy 109 103823. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103823","DOI":"10.1016\/j.drugpo.2022.103823"},{"key":"e_1_3_2_43_1","unstructured":"National Academies of Sciences Engineering and Medicine Health and Medicine Division Board on Health Sciences Policy Committee on Medication-Assisted Treatment for Opioid Mancher M. Leshner A. I. (2019). The Effectiveness of Medication-Based Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. National Academies Press (US). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541393\/"},{"key":"e_1_3_2_44_1","unstructured":"National Cancer Institute. (n.d.). About implementation science. NIH National Cancer Institute. https:\/\/cancercontrol.cancer.gov\/is\/about#:~:text=Implementation%20science%20(IS)%20is%20the our%20impact%20on%20population%20health"},{"key":"e_1_3_2_45_1","unstructured":"National Commission on Correctional Health Care & National Sheriffs\u2019 Association. (2025). Jail guidelines for the medical treatment of substance use disorders 2025. National Commission on Correctional Health Care. https:\/\/www.ncchc.org\/jail-based-mat\/"},{"key":"e_1_3_2_46_1","unstructured":"New York State Department of Health. (2022). Medication for Opioid Use Disorder (MOUD): Correctional health implementation toolkit. https:\/\/www.health.ny.gov\/diseases\/aids\/providers\/prevention\/harm_reduction\/buprenorphine\/docs\/moud_toolkit.pdf"},{"key":"e_1_3_2_47_1","unstructured":"Office of Public Affairs. (2022 April 5). Justice department issues guidance on protections for people with opioid use disorder under the Americans with Disabilities Act. United States Department of Justice. https:\/\/www.justice.gov\/archives\/opa\/pr\/justice-department-issues-guidance-protections-people-opioid-use-disorder-under-americans"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"Pivovarova E. Evans E. A. Stopka T. J. Santelices C. Ferguson W. J. Friedmann P. D. (2022). Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical correctional and jail administrator perspectives. Drug and Alcohol Dependence 234 109394. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109394","DOI":"10.1016\/j.drugalcdep.2022.109394"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","unstructured":"Pivovarova E. Taxman F. S. Boland A. K. Smelson D. A. Lemon S. C. Friedmann P. D. (2023). Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. Journal of Substance Use and Addiction Treatment 147 208950. https:\/\/doi.org\/10.1016\/j.josat.2022.208950","DOI":"10.1016\/j.josat.2022.208950"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","unstructured":"Pourtaher E. Gelberg K. H. Fallico M. Ellendon N. Li S. (2023). Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation. Journal of Substance Use and Addiction Treatment 161 209248. https:\/\/doi.org\/10.1016\/j.josat.2023.209248","DOI":"10.1016\/j.josat.2023.209248"},{"key":"e_1_3_2_51_1","doi-asserted-by":"crossref","unstructured":"Ranapurwala S. I. Shanahan M. E. Alexandridis A. A. Proescholdbell S. K. Naumann R. B. Edwards D. Marshall S. W. (2018). Opioid overdose mortality among former North Carolina inmates: 2000-2015. American Journal of Public Health 108(9) 1207\u20131213. https:\/\/doi.org\/10.2105\/AJPH.2018.304514","DOI":"10.2105\/AJPH.2018.304514"},{"key":"e_1_3_2_52_1","unstructured":"Roth E. Doolittle H. Chhean E. Tewarson H. (2025 January 21). Update on Medicaid section 1115 Waivers. NASHP. https:\/\/nashp.org\/january-2025-update-on-medicaid-section-1115-waivers\/"},{"key":"e_1_3_2_53_1","doi-asserted-by":"crossref","unstructured":"Ryan D. A. Montoya I. D. Koutoujian P. J. Siddiqi K. Hayes E. Jeng P. J. Cadet T. McCollister K. E. Murphy S. M. (2023). Budget impact tool for the incorporation of medications for opioid use disorder into jail\/prison facilities. Journal of Substance Use and Addiction Treatment 146 208943. https:\/\/doi.org\/10.1016\/j.josat.2022.208943","DOI":"10.1016\/j.josat.2022.208943"},{"key":"e_1_3_2_54_1","doi-asserted-by":"crossref","unstructured":"Saunders E. C. Satcher M. F. Monico L. B. McDonald R. D. Springer S. A. Farabee D. Gryczynski J. Nyaku A. Reeves D. Kunkel L. E. Schultheis A. M. Schwartz R. P. Lee J. D. Marsch L. A. Waddell E. N. (2022). The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: A cross-sectional study. Health & Justice 10(1) 35. https:\/\/doi.org\/10.1186\/s40352-022-00199-1","DOI":"10.1186\/s40352-022-00199-1"},{"key":"e_1_3_2_55_1","unstructured":"Sawyer W. Wagner P. (2025 March 11). Mass incarceration: The whole pie 2025. Prison and Policy Initiative. https:\/\/www.prisonpolicy.org\/reports\/pie2025.html"},{"key":"e_1_3_2_56_1","doi-asserted-by":"crossref","unstructured":"Scott C. K. Grella C. E. Dennis M. L. Carnevale J. LaVallee R. (2022). Availability of best practices for opioid use disorder in jails and related training and resource needs: Findings from a national interview study of jails in heavily impacted counties in the U.S. Health & Justice 10(1) 36. https:\/\/doi.org\/10.1186\/s40352-022-00197-3","DOI":"10.1186\/s40352-022-00197-3"},{"key":"e_1_3_2_57_1","unstructured":"Solomon A. L. Moore K. F. McLearen A. M. & Office of Justice Programs Bureau of Justice Assistance. (2023). Guidelines for managing substance withdrawal in jails: A tool for local government officials jail administrators correctional officers and health care professionals. U.S. Department of Justice Office of Justice Programs. https:\/\/bja.ojp.gov\/doc\/guidelines-managing-substance-withdrawal-jails.pdf"},{"key":"e_1_3_2_58_1","doi-asserted-by":"crossref","unstructured":"Staton M. Pike E. Levi M. Lofwall M. (2023). The importance of justice and health care partnerships in MOUD feasibility trials. Journal of Social Work Practice in the Addictions. https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/1533256X.2023.2178119","DOI":"10.1080\/1533256X.2023.2178119"},{"key":"e_1_3_2_59_1","doi-asserted-by":"crossref","unstructured":"Staton M. Pike E. Tillson M. Lofwall M. R. (2023). Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia. Journal of Community Psychology 52(8) 997\u20131014. https:\/\/doi.org\/10.1002\/jcop.23029","DOI":"10.1002\/jcop.23029"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","unstructured":"Stopka T. J. Rottapel R. E. Ferguson W. J. Pivovarova E. Toro-Mejias L. D. Friedmann P. D. Evans E. A. (2022). Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. The International Journal on Drug Policy 110 103803. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103803","DOI":"10.1016\/j.drugpo.2022.103803"},{"key":"e_1_3_2_61_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2019 July). Use of medication-assisted treatment for opioid use disorder in criminal justice settings. SAMHSA Library. https:\/\/library.samhsa.gov\/product\/Use-of-Medication-Assisted-Treatment-for-Opioid-Use-Disorder-in-Criminal-Justice-Settings\/PEP19-MATUSECJS"},{"key":"e_1_3_2_62_1","doi-asserted-by":"crossref","unstructured":"Sufrin C. Kramer C. T. Terplan M. Fiscella K. Olson S. Voegtline K. Latkin C. (2023). Availability of medications for opioid use disorder in U.S. jails. Journal of General Internal Medicine 38(6) 1573\u20131575. https:\/\/doi.org\/10.1007\/s11606-022-07812-x","DOI":"10.1007\/s11606-022-07812-x"},{"key":"e_1_3_2_63_1","doi-asserted-by":"crossref","unstructured":"Sufrin C. Kramer C. T. Terplan M. Fiscella K. Olson S. Voegtline K. Latkin C. (2022). Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails. JAMA Network Open 5(1) e2144369. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44369","DOI":"10.1001\/jamanetworkopen.2021.44369"},{"key":"e_1_3_2_64_1","doi-asserted-by":"crossref","unstructured":"Sufrin C. Sutherland L. Beal L. Terplan M. Latkin C. Clarke J. G. (2020). Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: Results from a national surveillance study. Addiction 115(11) 2057\u20132065. https:\/\/doi.org\/10.1111\/add.15030","DOI":"10.1111\/add.15030"},{"key":"e_1_3_2_65_1","unstructured":"Teixeira da Silva D. O\u2019Brien J. Wachino V. (2023). Recommendations for Medicaid coverage of opioid use disorder services in jails and prisons. Viaduct Consulting. https:\/\/healthandreentryproject.org\/wp-content\/uploads\/2023\/10\/Recommendations-for-Medicaid-Coverage-of-OUD-Services-in-Jails-and-Prison.pdf"},{"key":"e_1_3_2_66_1","doi-asserted-by":"crossref","unstructured":"Thakrar A. P. Alexander G. C. Saloner B. (2021). Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. JAMA Network Open 4(12) e2138807. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.38807","DOI":"10.1001\/jamanetworkopen.2021.38807"},{"key":"e_1_3_2_67_1","doi-asserted-by":"crossref","unstructured":"Thomas S. Singer A. Kopak A. (2023). Receptivity to Jail-based medication for opioid use disorder among rural detention Administrators. Corrections 9(4) 517\u2013535. https:\/\/doi.org\/10.1080\/23774657.2023.2278195","DOI":"10.1080\/23774657.2023.2278195"},{"key":"e_1_3_2_68_1","doi-asserted-by":"crossref","unstructured":"Treitler P. C. Enich M. Reeves D. Crystal S. (2022). Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons. Substance Abuse 43(1) 964\u2013971. https:\/\/doi.org\/10.1080\/08897077.2022.2060448","DOI":"10.1080\/08897077.2022.2060448"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","unstructured":"Victor G. Lee G. Pozo B. del Silverstein S. Zettner C. Cason R. Ray B. (2022). Medications for opioid use disorder in the criminal\/legal system: Knowledge beliefs and attitudes among rural community-based stakeholders. Journal of Drug Issues 52(3) 389\u2013405. https:\/\/doi.org\/10.1177\/00220426221076800","DOI":"10.1177\/00220426221076800"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","unstructured":"Whaley S. Bandara S. Taylor K. Krawczyk N. (2023). Expanding buprenorphine in U.S. jails: One county\u2019s response to addressing the fears of diversion. Journal of Substance Use and Addiction Treatment 146 208944. https:\/\/doi.org\/10.1016\/j.josat.2022.208944","DOI":"10.1016\/j.josat.2022.208944"},{"key":"e_1_3_2_71_1","doi-asserted-by":"crossref","unstructured":"Zielinski M. J. Allison M. K. Brinkley-Rubinstein L. Curran G. Zaller N. D. Kirchner J. A. E. (2020). Making change happen in criminal justice settings: Leveraging implementation science to improve mental health care. Health & Justice 8(1) 21. https:\/\/doi.org\/10.1186\/s40352-020-00122-6","DOI":"10.1186\/s40352-020-00122-6"}],"container-title":["Medical Care Research and Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10775587251345018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10775587251345018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10775587251345018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:33:35Z","timestamp":1777685615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10775587251345018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/10775587251345018"],"URL":"https:\/\/doi.org\/10.1177\/10775587251345018","relation":{},"ISSN":["1077-5587","1552-6801"],"issn-type":[{"value":"1077-5587","type":"print"},{"value":"1552-6801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}